Table 1.
Compounds to inhibit lactate production.
| Target | Drug | Type of Cancer or Cell/Animal Model | Research Phase | References |
|---|---|---|---|---|
| LDH | FX-11 | B-lymphoid cells (P493, P198) Xenograft model | Pre-clinical | [167] |
| Gossypol AT-10 | Multiple kinds of cancer | Phase I and Phase II clinical trialsa | [171,172] | |
| Galloflavin | Liver cancer (PLC/PRF/5) Hepatocellular carcinoma |
Pre-clinical | [168,174] | |
| N-hydroxyindole-based compounds | Colon (Caco-2, HCT116 and HT29) Bladder (5637, HT1197, HT1376, RT4, SW780, T24, TCCSUP and UM-UC-3) | Pre-clinical | [169] | |
| FX866 | Pancreatic cancer (P198) Xenograft model |
Pre-clinical | [167] | |
| Oxamate | Hepatocellular carcinoma Medulloblastoma | Pre-clinical | [174,175] | |
| 2 Thio-6-oxo1,6-dihydropyrinidine (DHPMs) |
Pancreatic carcinoma (MIA PaCa-2) Mouse model |
Pre-clinical | [176] | |
| GNE-140 | Colon adenocarcinoma (LS174T) Mouse model Pancreatic carcinoma (MIA PaCa-2) |
Pre-clinical | [177,178] | |
| Pyzazole based inhibitors | Pancreatic carcinoma (MIA PaCa-2) A673 Sarcoma (A673) |
Pre-clinical | [179] | |
| 1-(Phenylseleno)-4-(Trifluoromethyl) Benzene (PSTMP) | Large cell lung cancer (NCI-H460) Breast cancer (MCF-7) Hepatocellular carcinoma (Hep3B) Malignan melanoma (A375) Colorectal adenocarcinoma (HT29) Murine lung cancer (LLC) |
Pre-clinical | [180] | |
| Compound 11 | Osteosarcoma (MG-63) | Pre-clinical | [181] | |
| Compound 24c | Pancreas carcinoma (MiaPaCa-2) | Pre-clinical | [182] | |
| Peptides collections (QLYNL, LIYNLL, IYNLLK, KWYNVA, and KVVYNV) | None | In silico modeling | [183] |
Notes: a ClinicalTrials.gov identifier: NCT01791595.